Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients

Atrial FibrillationHeart Failure

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure

ESC Heart Fail.

Martinez BK, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI

doi: 10.1002/ehf2.12365.

Atrial FibrillationThrombosis and Stroke

Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban

Am J Cardiol.

Bai Y, Shi XB, Ma CS, Lip GYH

doi: 10.1016/j.amjcard.

Atrial Fibrillation

Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology

Circ Arrhythm Electrophysiol.

Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Mazzone P, Foley D, Grygier M, Sievert H, De Potter T, Vireca E, Stein K, Bergmann MW, following investigators and institutions participated in the EWOLUTION study

doi: 10.1161/CIRCEP.

Atrial Fibrillation

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation

JAMA Intern Med.

Lutsey PL, Norby FL, Ensrud KE, MacLehose RF, Diem SJ, Chen LY, Alonso A

doi: 10.1001/jamainternmed.2019.5679.

Atrial Fibrillation

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study

J Cardiovasc Med (Hagerstown).

De Caterina R, Kelly P, Monteiro P3, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators

doi: 10.2459/JCM.

Atrial Fibrillation

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

BMC Cardiovasc Disord.

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P, ETNA-AF-Europe investigators.

doi: 10.1186/s12872-019-1144-x.

Atrial FibrillationHeart FailureHypertensionThrombosis and Stroke

Global Prospective Safety Analysis of Rivaroxaban

J Am Coll Cardiol.

Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators

doi: 10.1016/j.jacc.2018.04.058.

Heart Failure

Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice

J Am Coll Cardiol.

Desai AS, Bhimaraj A, Bharmi R, Jermyn R, Bhatt K, Shavelle D, Redfield MM, Hull R, Pelzel J, Davis K, Dalal N, Adamson PB, Heywood JT

doi: 10.1016/j.jacc.2017.03.009.

Heart, Artery and Coronary DiseasesThrombosis and StrokeTherapy and Intervention

Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison

J Am Coll Cardiol.

Brennan JM, Thomas L, Cohen DJ, Shahian D, Wang A, Mack MJ, Holmes DR, Edwards FH, Frankel NZ, Baron SJ, Carroll J, Thourani V, Tuzcu EM, Arnold SV, Cohn R, Maser T, Schawe B, Strong S, Stickfort A, Patrick-Lake E, Graham FL, Dai D, Li F, Matsouaka RA, O'Brien S, Li F, Pencina MJ, Peterson ED

doi: 10.1016/j.jacc.2017.05.060.

Related content

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure

Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban

Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

Global Prospective Safety Analysis of Rivaroxaban

Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice

Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison